• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of clinical rheumatology. >Collagenase clostridium histolyticum effective in the nonsurgical treatment of Dupuytrens contracture
【24h】

Collagenase clostridium histolyticum effective in the nonsurgical treatment of Dupuytrens contracture

机译：胶原酶溶组织梭状芽胞杆菌在非手术治疗Dupuytrens挛缩中有效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Results from the Collagenase Option for the Reduction of Dupuytrens (CORD II) study have been published in The Journal of Hand Surgery, demonstrating the beneficial role of collagenase clostridium histolyticum (Xiaflex~R, Auxilium Pharmaceuticals Inc., PA, USA) in the nonsurgical treatment for Dupuytren's contracture.Collagenase Option for the Reduction of Dupuytren's II, was a prospective, mul-ticenter, Phase III study that investigated the efficacy and safety of injectable collagenase clostridium histolyticum in patients with Dupuytren's contracture, estimated to affect up to 13% of the population in Europe. The 12-month study involved two phases: a 90-day randomized, double-blind, placebo-controlled phase and a 9-month open-label phase. It involved a total of 66 patients, with Dupuytren's cords from either metacarpophalangeal or proximal interphalangeal joints injected with collagenase clostridium histolyticum.
机译：《减少手足癣的胶原酶选择研究》的结果已发表在《手外科杂志》上，证明了胶原酶溶组织梭状芽胞杆菌（Xiaflex〜R，Auxilium Pharmaceuticals Inc.，PA，美国）的非手术作用。多普勒特氏挛缩症的胶原酶治疗方案是一项前瞻性，多中心，III期研究，旨在研究可注射胶原酶溶组织性梭状芽胞杆菌对多普特勒氏挛缩症的疗效和安全性，估计最多可影响13％欧洲的人口。这项为期12个月的研究包括两个阶段：90天随机，双盲，安慰剂对照阶段和9个月开放标签阶段。该病例共66例患者，注射了胶原酶组织溶解梭状芽胞杆菌，从掌指或近指间关节的Dupuytren脐带。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号